Back to News
Market Impact: 0.35
Cosmo Reports Positive Phase 2 Results For Rifamycin Gel In Ulcerative Colitis
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Cosmo N.V. reported positive topline results from a phase 2 study of rifamycin 1% topical gel in patients with mildly to moderately active distal ulcerative colitis and ulcerative proctitis. The article provides no efficacy figures, safety details, or further development timeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
More News
- BlackRock, GIC among investors chasing Indian telecom major Jio's IPO as anchor bids top $26 billion
- Gartner analyst behind tech rout: AI returns are not yet large enough to justify neocloud build-out
- Walmart’s Flipkart is quietly building a food delivery challenger in India
- Credit stress is threatening to unwind the AI bull. All eyes are on Oracle to hold the line
- LightStream stops accepting loan applications. Try these 6 lenders instead
- Ciena EVP DiPerna sells $308,865 in CIEN stock
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Index and ETF Holdings Data for AI Research
- Capital Intensity as Gravity: The AI Trade Enters Its Industrial Era (Looking at Q3 2025 Earnings in Tech)